CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2022;28(2):254-264.   Published online 2021 December 28    DOI: https://doi.org/10.3350/cmh.2021.0314

Excel Download

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Clinical and Molecular Hepatology. 2022;28(2):254-264   Crossref logo
Link1 Link2 Link3

PGI3 Comparative Safety of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in Chronic Hepatitis B Patients
Value in Health. 2020;23:S533   Crossref logo
Link1 Link2

250 - Renal Outcomes in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Entecavir: A Propensity Score Matched Study
Gastroenterology. 2018;154(6):S-1081   Crossref logo
Link1 Link2

Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study
Journal of Hepatology. 2018;68:S519-S520   Crossref logo
Link1 Link2

P1-086: Effect of vitamin D on treatment response in chronic hepatitis C patients: a propensity score stratification and multilevel analysis
Journal of Viral Hepatitis. 2018;25:66-67   Crossref logo
Link1 Link2

Is renal impairment associated with chronic hepatitis B - a propensity score matched study of healthy non-hepatitis B patients compared to patients with untreated chronic hepatitis B
Journal of Hepatology. 2018;68:S512-S513   Crossref logo
Link1 Link2

O-043: Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
Journal of Viral Hepatitis. 2018;25:27-27   Crossref logo
Link1 Link2

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
JGH Open. 2020;5(2):258-263   Crossref logo
Link1 Link2 Link3

Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study
The Journal of Infectious Diseases. 2018;219(1):10-18   Crossref logo
Link1

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
Drug Design, Development and Therapy. 2017;Volume 11:3197-3204   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.